Anders Hove has joined Arca Biopharma’s board of directors.
“Anders brings decades of experience building and advising biopharmaceutical companies,” says Michael R Bristow, president and chief executive officer of ARCA. “With his expertise on both the corporate and investment sides of the industry, Anders’ input and guidance will be valuable to our Board of Directors as we continue the development of bucindolol (Gencaro).”
Hove has more than 20 years of experience investing in and helping build biopharmaceutical companies. He has served on the Boards of Directors of numerous private and public companies, currently serving on the Boards of two private biopharmaceutical companies.
In 2011, Hove was named to Forbes’ Midas List, which ranked the top venture capitalists in life sciences and technology.
Hove received a master’s of science degree in biotechnology engineering from the Technical University of Denmark, Kongens Lyngby, Denmark, a medical degree from the University of Copenhagen, Copenhagen, Denmark, and a master’s of business administration from the Institut Européen d’Administration des Affaires, Fontainebleau, France.
Hove says, “This is an exciting time for the organisation with the GENETIC-AF clinical trial interim efficacy analysis expected later this year. I believe there is a significant opportunity for developing genetically-targeted cardiovascular therapeutics, for which ARCA is well-positioned.”
